Immunologic Responses After COVID-19 Vaccination in Patients With Membranous Nephropathy Receiving Anti–CD38 Felzartamab Therapy: Results From the Phase 1b/2a M-PLACE Study

Detalles Bibliográficos
Autores principales: Rovin, Brad H., Boxhammer, Rainer, Thakur, Anjali, Ronco, Pierre M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9186646/
https://www.ncbi.nlm.nih.gov/pubmed/35702397
http://dx.doi.org/10.1016/j.ekir.2022.05.031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9186646/
https://www.ncbi.nlm.nih.gov/pubmed/35702397
http://dx.doi.org/10.1016/j.ekir.2022.05.031

Ejemplares similares